Semaglutide seems to be more effective the other GLP-1Ras

Affiliations

¹ Department of Biomedical Sciences, Copenhagen University Hospital Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
² Department of Endocrinology, Copenhagen University Hospital Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Editorial

Jens Juul Holst et al. Ann Transl Med. 2017 Dec.

. 2017 Dec;5(24):505.

doi: 10.21037/atm.2017.11.10.

¹ Department of Biomedical Sciences, Copenhagen University Hospital Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
² Department of Endocrinology, Copenhagen University Hospital Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Erratum in

Erratum to semaglutide seems to be more effective the other GLP-1Ras.
Holst JJ, Madsbad S. Holst JJ, et al. Ann Transl Med. 2018 Feb;6(3):74. doi: 10.21037/atm.2018.01.20. Ann Transl Med. 2018. PMID: 29611550 Free PMC article.

No abstract available

Conflicts of Interest: The authors have no conflicts of interest to declare.

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Sorli C, et al. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42. 10.1007/s00125-014-3460-0 - DOI - PubMed
1. Østergaard L, Frandsen CS, Madsbad S. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol 2016;9:241-65. 10.1586/17512433.2016.1121808 - DOI - PubMed
1. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42. 10.1038/nrendo.2012.140 - DOI - PubMed
1. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4. 10.1007/BF00401145 - DOI - PubMed
1. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006;49:253-60. 10.1007/s00125-005-0107-1 - DOI - PubMed